Daratumumab (anti-CD38) induces loss of CD38 on red blood cells

Blood. 2017 Jun 1;129(22):3033-3037. doi: 10.1182/blood-2016-11-749432. Epub 2017 Apr 3.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1 / blood*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects*
  • Erythrocytes* / metabolism
  • Erythrocytes* / pathology
  • Female
  • Humans
  • Male
  • Membrane Glycoproteins / blood*
  • Multiple Myeloma* / blood
  • Multiple Myeloma* / diet therapy
  • Multiple Myeloma* / pathology

Substances

  • Antibodies, Monoclonal
  • Membrane Glycoproteins
  • daratumumab
  • CD38 protein, human
  • ADP-ribosyl Cyclase 1